Login
Companies $PMVP
$1.15 -$0.04 (3.28%) After hours
PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

pmvpharma.com

What Do They Do?

Develops small-molecule precision cancer therapies designed to correct mutant tumor-suppressor proteins, including rezatapopt for patients with cancers linked to a specific mutation.

Who Are Their Customers?

If approved, the company plans to sell its products through a focused sales and marketing organization to oncologists, who treat the patient populations for which its candidates are being developed.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −63% (Loss)
vs −$21.1M in Q3 FY2025
  • Aug 31, 2026 PMV Pharma priced a $50.8 million public offering The offering included common shares or pre-funded warrants and accompanying warrants.
  • Aug 31, 2026 Rezatapopt interim ovarian cancer data showed a 46% response rate The company said FDA feedback supported its plan to seek accelerated approval and submit an application in the first quarter of 2027.

Broader platform focus The older report described applying its platform to hotspot mutations in the tumor-suppressor protein and inhibitors of its normal form; the latest describes candidates targeting mutant forms of the protein or related cancers.

Who Do They Compete With?

Competes with Jacobio Pharmaceuticals, Changchun GeneScience, Frontier Medicines, and Nutshell Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support